Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: A preliminary study

Clinical Kidney Journal

Volumn 6, Issue 2, 2013, Pages 164-168

  Hadjiyannakos, Dimitrios ^a   Filiopoulos, Vassilis ^a   Trompouki, Sofia ^a   Sonikian, Makroui ^a   Karatzas, Ioannis ^a   Panagiotopoulos, Konstantinos ^a   Vlassopoulos, Dimosthenis ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

CKD stage 3 and 4; oral paricalcitol; parathyroid hormone; secondary hyperparathyroidism; vitamin D

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCIUM; CREATININE; HEMOGLOBIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL PRACTICE; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FUNCTION; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; SECONDARY HYPERPARATHYROIDISM; URINARY EXCRETION;

EID: 84875754912     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs188     Document Type: Article

References (35)

1. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38
2. Adress DL. Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin J Am Soc Nephrol 2008; 3: 179-183
3. Bover J, Cozzolino M. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. Kidney Int Suppl 2011; 1: 122-129
4. Larsson T, Vervloet M. Fibroblast growth factor-23 and klotho in chronic kidney disease. Kidney Int Suppl 2011; 1: 130-135
5. Adress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005; 18: 315-321
6. Sprague SM, Coyne D. Control of secondary hyperparathyroid-ism by vitamin D receptors agonists in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 512-518
7. Martin KJ, Gonzalez EA. Vitamin D supplementation in CKD. Clin Nephrol 2011; 75: 286-293
8. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on he-modialysis. J Am Soc Nephrol 1998; 9: 1427-1432
9. Lindberg J, Martin KJ, Gonzalez EA et al. A long-term, multi-center study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56: 315-323
10. Ross EA, Tian J, Abboud H et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on he-modialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106
11. Abdul Gafor AH, Saidin R, Loo CY et al. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology (Carlton) 2009; 14: 488-492
12. Mittman N, Desiraju B, Meyer KB et al. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single center crossover study. Kidney Int 2010; 78: S33-S36
13. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28
14. Patel TV, Singh AK. Role of vitamin D in chronic kidney disease. Semin Nephrol 2009; 29: 113-121
15. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276
16. Kovesdy CP, Lu JL, Malakauskas SM et al. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 2012; 59: 58-66
17. Sánchez H, Garrido P, Moyano P et al. Effectiveness of treatment with oral paricalcitol in patients with predialysis chronic kidney disease. Nefrologia 2011; 31: 697-706
18. Brandenburg VM, Ketteler M, Rondriguez M. Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps. Kidney Int Suppl 2011; 1: 116-121
19. Bianchi ML, Colantonio G, Campanini F et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994; 9:1595-1599
20. Ritz E, Küster S, Schmidt-Gayk H et al. Low dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995; 10: 2228-2234
21. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363
22. Winterborn ME, Mace PJ, Heath DA et al. Impairment of renal function in patients on 1a-hydroxycholecalciferol. Lancet 1978; 2: 150-151
23. Christiansen C, Rodbro P, Christiansen MS et al. Deterioration of renal function during treatment of chronic renal failure with 1,25- hydroxycholecalciferol. Lancet 1978; 2: 700-703
24. Bertoli M, Luisetto G, Ruffatti A et al. Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 1990; 33: 98-102
25. Perez A, Raab R, Chen JC et al. Efficacy and safety of oral calcitriol (1.25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134:1070-1078
26. 3 and renal function. Acta Med Scan 1982; 211: 51-54
27. 2D3: Humoral and histo-morphometric results. Miner Electrolyte Metab 1986; 12: 375-382
28. 3 administration in a long-term follow-up. Kidney Int 1985; 28: 783-790
29. Shidara K, Inaba M, Kumeda Y et al. Significance of serum PTH (7-84) as a reliable nutritional marker in hemodialysis patients. Clin Calcium 2006; 16:149-152
30. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828
31. Fishbane S, Chittineni H, Packman M et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647-52
32. De Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet 2010; 376:1543-1551
33. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-KB signaling. J Am Soc Nephrol 2008; 19:1741-1752
34. He W, Kang YS, Dai C et al. Blockade of Wnt/p-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011; 22: 90-103
35. Cheng J, Zhang W, Zhang X et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012; 7: 391-400